A Single Center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-G3031 after Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects

Trial Profile

A Single Center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-G3031 after Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs SUVN G3031 (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Adverse reactions; First in man
  • Sponsors Suven Life Sciences
  • Most Recent Events

    • 19 Oct 2015 Results presented at the annual meeting of the Society for Neuroscience (SFN) 2015, as per Suven Life Science media release.
    • 08 Sep 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 13 Apr 2015 Results of single ascending dose studies published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top